Supplementary Data for Apremilast versus betamethasone oral mini-pulse in the treatment of progressive non-segmental vitiligo: a non-inferiority randomized controlled trial

Mendeley Supplementary Figure 1. Proportion of patients achieving disease arrest in both treatment arms at each visit (per-protocol analysis) Mendeley Supplementary Figure 2. Change in proportion of patients with different Vitiligo Disease Area (VIDA) Score in each treatment arm over study duration, A. Apremilast, B. Betamethasone oral mini-pulse (no intergroup difference, p=0.337)门德雷（Mendeley）补充图1：各访视时点两个治疗组中达到病情静止的患者占比（符合方案集分析） 门德雷（Mendeley）补充图2：研究周期内各治疗组中不同白癜风疾病面积（Vitiligo Disease Area, VIDA）评分患者占比的变化，A. 阿普斯特（Apremilast）；B. 口服迷你脉冲倍他米松（Betamethasone）（组间无统计学差异，p=0.337）